Kura Oncology Reports Preliminary Proof Of Mechanism Data From Early-Stage In Head & Neck Cancer

Kura Oncology Inc KURA reported proof of mechanism in KURRENT-HN Phase 1/2 trial of tipifarnib in combination with alpelisib in patients with HRAS-and/or PIK3CA-dependent head and neck squamous cell carcinoma (HNSCC).
Kura highlights a patient with stage III squamous cell carcinoma of the tonsil, including a PIK3CA mutation and HRAS overexpression, who has achieved a durable partial remission on the study.
After failing two prior treatments, the 35-year-old patient enrolled in KURRENT-HN experienced an 81% reduction in target lesions after one cycle of tipifarnib and alpelisib and an 84% reduction after three cycles.
Related: Read Why Did Credit Suisse Raise Price Target On Kura Oncology.
As of September 14, 2022, the patient continued on the study for more than 27 weeks.
Although tipifarnib has shown single-agent clinical activity in a highly selected population of HRAS mutant HNSCC, alpelisib has shown single-agent clinical activity in patients with PIK3CA-mutant, ER-positive/HER2-negative breast cancer, no objective responses have been observed with either agent as a monotherapy in patients with PIK3CA-mutant HNSCC.
Price Action: KURA shares are down 3.30% at $15.98 on the last check Wednesday.